Global Cold Sore Treatment Market, Strain Type (Herpes Simplex Type-1 Virus, Herpes Simplex Type-2 Virus), Therapeutics Type (Antiviral Agents, Analgesic Agents, Others), Drug Type (Branded, Generics), Dosage Form (Tablet, Capsule, Ointment, Others), Route of Administration (Oral, Topical, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2030.
Cold Sore Treatment Market Analysis and Size
According to World Health Organization statistics, from 2020, around 3.7 million persons nationwide were infected with HSV 1. Direct contact with infected skin or saliva transmits the HSV-1 virus. Primary infection can produce a fever, aching gums, a sore throat, and swollen or irritated glands in the neck in children. The virus then becomes dormant in nerve roots close to the affected skin. The virus only rarely, if ever, reactivates in certain persons. Recurrences of the virus, known as secondary herpes episodes, can occur in certain people, resulting in cold sores. While the exact reason of reactivation has yet to be discovered, a range of factors, such as stress, dental treatment, illness, lip trauma, or sun exposure, might trigger an outbreak.
Data Bridge Market Research analyses that the cold sore treatment market was valued at USD 825.24 million in 2022 and is expected to reach USD 1,376.06 million by 2030, registering a CAGR of 6.60% during the forecast period of 2023 to 2030. ‘”Antiviral agents” dominates therapeutics type segment in the market as most of the cold are caused by common viral cold fever.
In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include in-depth expert analysis, geographically represented company-wise production and capacity, network layouts of distributors and partners, detailed and updated price trend analysis and deficit analysis of supply chain and demand.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Strain Type (Herpes Simplex Type-1 Virus, Herpes Simplex Type-2 Virus), Therapeutics Type (Antiviral Agents, Analgesic Agents, Others), Drug Type (Branded, Generics), Dosage Form (Tablet, Capsule, Ointment, Others), Route of Administration (Oral, Topical, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina, and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Merck & Co., Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Cipla Inc. (U.S.), Hologic, Inc. (U.S.), BD (U.S.), Bristol-Myers Squibb Company (U.S.), Gilead Sciences, Inc. (U.S.), Bayer AG (Germany), Eli Lilly and Company (U.S.), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), and Bausch Health Companies Inc. (Canada)
|
|
Market Opportunities
|
|
Market Definition
A cold sore is a fluid-filled blister that occurs on the lips or around the mouth. Fever blisters, oral herpes, and herpes labialis are all terms used to describe cold sores. Herpes simplex is the virus that causes them. Herpes simplex virus 1 is the most prevalent strain of the virus that causes cold sores. Antiviral ointments, including acyclovir and penciclovir, are applied on sores as part of the treatment. These may work for some people, but they are frequently ineffective. Antiviral oral drugs such as famciclovir, acyclovir and valacyclovir can help reduce the duration and severity of sores. Symptoms may be relieved by applying over-the-counter pain relievers to the sores (topical). Anti-inflammatory drugs could potentially be beneficial.
Global Cold Sore Treatment Market Dynamics
Drivers
- High Prevalence Rate of HSV Infection
The rising prevalence of HSV infection across the globe will act as a major driver that will result in the expansion of the market's growth rate. In persons with long-term or chronic conditions, HSV increases the chance of acquiring and transmitting HIV infection and can cause significant complications such as encephalitis and keratitis. This, combined with the rising number of patients with chronic conditions, is one of the major factors driving the demand for HSV therapy worldwide.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of cold sore treatment market is the rising healthcare expenditure which helps in improving its infrastructure. In addition, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.
Furthermore, a surging number of government initiatives to spread awareness and increase the geriatric population will expand the cold sore treatment market. In addition, rising level of disposable income and growing government favorable initiatives will enhance the market's growth rate.
Opportunity
- Lack of Drug Calls for New Medicine
The market's growth is fueled by lack of drug calls for new medicine. This will provide beneficial opportunities for the cold sore treatment market growth. There are only a few medicines available to treat cold sore on the market. This encourages pharmaceutical companies to produce new medications. The players are doing this by incorporating new technologies that will allow them to isolate the molecule for treatment. Furthermore, the issues of maintaining optimal pharmacokinetics and pharmacodynamics of medications are providing pharmaceutical firms with profitable opportunities.
Moreover, the market's growth is fueled by investment to develop advanced technologies and increase the number of emerging markets. These factors will provide beneficial opportunities for the cold sore treatment market growth.
Restraint/Challenge
- High Cost Associated with Treatment
On the other hand, the high cost associated with the treatment will obstruct the growth rate of the cold sore treatment market during 2023-2030. The lack of healthcare infrastructure in developing economies and strict regulatory scenario will challenge the cold sore treatment market. In addition, lack of awareness among people and poor reimbursement policies will restrain and further impede the market's growth rate during the forecast period of 2023-2030.
This cold sore treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the cold sore treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
This cold sore treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the cold sore treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In July 2021, Devirex had announced the launch of lipivir. Devirex is beginning a new phase of development: what was developed in the lab will be gradually distributed to other markets. Lipivir(R) lip gel, which prevents cold sores, was accessible in pharmacies, drugstores, beauty spas, and online in early 2021 in Switzerland and Austria after hundreds of hours of creation, research, and analysis
Global Cold Sore Treatment Market Scope
The cold sore treatment market is segmented on the basis of strain type, therapeutics type, drug type, dosage form, route of administration, end-users, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Strain Type
- Herpes Simplex Type-1 Virus
- Herpes Simplex Type-2 Virus
Therapeutics Type
- Antiviral Agents
- Acyclovir
- Valacyclovir
- Famciclovir
- Penciclovir
- Analgesic Agents
- Lysine
- Rhubarb and sage
- Propolis
- Others
Drug Type
- Branded
- Generics
Dosage Form
- Tablet
- Capsule
- Ointment
- Others
Route of Administration
- Oral
- Topical
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Global Cold Sore Treatment Market Regional Analysis/Insights
The cold sore treatment market is analysed and market size insights and trends are provided by country, strain type, therapeutics type, drug type, dosage form, route of administration, end-users, and distribution channel as referenced above.
The countries covered in the global cold sore treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina, and rest of South America.
North America dominates the cold sore treatment market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the growing target population and rising healthcare expenditure will further propel the market's growth rate in this region. Additionally, the presence of major key players and rising consumer's awareness about the STD diseases will further propel the market's growth rate in this region.
Asia-Pacific is expected to be the fastest-growing region during the forecast period of 2023-2030 due to growing number of patient population in this region. Also, development of healthcare infrastructure and rising government initiatives will further propel the market's growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The global feminine hygiene products market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the market in the historic period of 2011-2021.
Competitive Landscape and Cold Sore Treatment Market Share Analysis
The cold sore treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the market.
Some of the major players operating in the cold sore treatment market are:
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (U.K.)
- Novartis AG (Switzerland)
- Mylan N.V. (U.S.),
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Merck & Co., Inc. (U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Cipla Inc. (U.S.)
- Hologic, Inc. (U.S.)
- BD (U.S.)
- Bristol-Myers Squibb Company (U.S.)
- Gilead Sciences, Inc. (U.S.)
- Bayer AG (Germany)
- Eli Lilly and Company (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- Bausch Health Companies Inc. (Canada)
SKU-